Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VanaLice is an over-the-counter (OTC) topical gel developed and marketed by GM Pharmaceuticals for the treatment of lice infestations (pediculosis), including head lice, pubic (crab) lice, and body lice. The product is a combination of two active pediculicides: **pyrethrins** (derived from pyrethrum extract) and **piperonyl butoxide**. Pyrethrins function as neurotoxins that disrupt the nervous system of lice by prolonging the opening of voltage-gated sodium channels, leading to paralysis and death. Piperonyl butoxide acts as a synergist by inhibiting the cytochrome P450 enzymes in the lice that would otherwise metabolize and detoxify the pyrethrins. The formulation also incorporates essential oils such as tea tree, coconut, and lemongrass oil. It is indicated for use in adults and children aged 2 years and older and is typically supplied as a kit including a fine-tooth nit removal comb.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VanaLice.